442 related articles for article (PubMed ID: 35328658)
1. Targeting DNA Damage Response and Immune Checkpoint for Anticancer Therapy.
Huang JL; Chang YT; Hong ZY; Lin CS
Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328658
[TBL] [Abstract][Full Text] [Related]
2. The complementarity of DDR, nucleic acids and anti-tumour immunity.
Kornepati AVR; Rogers CM; Sung P; Curiel TJ
Nature; 2023 Jul; 619(7970):475-486. PubMed ID: 37468584
[TBL] [Abstract][Full Text] [Related]
3. Mutations in DNA damage response pathways as a potential biomarker for immune checkpoint blockade efficacy: evidence from a seven-cancer immunotherapy cohort.
Zhang W; Zhang L; Jiang H; Li Y; Wang S; Wang Q
Aging (Albany NY); 2021 Nov; 13(21):24136-24154. PubMed ID: 34747718
[TBL] [Abstract][Full Text] [Related]
4. Function and Molecular Mechanism of the DNA Damage Response in Immunity and Cancer Immunotherapy.
Ye Z; Shi Y; Lees-Miller SP; Tainer JA
Front Immunol; 2021; 12():797880. PubMed ID: 34970273
[TBL] [Abstract][Full Text] [Related]
5. Targeting DNA damage response and repair genes to enhance anticancer immunotherapy: rationale and clinical implication.
Lamberti G; Andrini E; Sisi M; Federico AD; Ricciuti B
Future Oncol; 2020 Aug; 16(23):1751-1766. PubMed ID: 32539551
[TBL] [Abstract][Full Text] [Related]
6. The role of DNA damage repair (DDR) system in response to immune checkpoint inhibitor (ICI) therapy.
Shi C; Qin K; Lin A; Jiang A; Cheng Q; Liu Z; Zhang J; Luo P
J Exp Clin Cancer Res; 2022 Sep; 41(1):268. PubMed ID: 36071479
[TBL] [Abstract][Full Text] [Related]
7. The DNA damage induced immune response: Implications for cancer therapy.
Barros EM; McIntosh SA; Savage KI
DNA Repair (Amst); 2022 Dec; 120():103409. PubMed ID: 36308822
[TBL] [Abstract][Full Text] [Related]
8. Interfaces between cellular responses to DNA damage and cancer immunotherapy.
Pilger D; Seymour LW; Jackson SP
Genes Dev; 2021 May; 35(9-10):602-618. PubMed ID: 33888558
[TBL] [Abstract][Full Text] [Related]
9. Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer.
Sen T; Rodriguez BL; Chen L; Corte CMD; Morikawa N; Fujimoto J; Cristea S; Nguyen T; Diao L; Li L; Fan Y; Yang Y; Wang J; Glisson BS; Wistuba II; Sage J; Heymach JV; Gibbons DL; Byers LA
Cancer Discov; 2019 May; 9(5):646-661. PubMed ID: 30777870
[TBL] [Abstract][Full Text] [Related]
10. Alterations of DNA damage response pathway: Biomarker and therapeutic strategy for cancer immunotherapy.
Jiang M; Jia K; Wang L; Li W; Chen B; Liu Y; Wang H; Zhao S; He Y; Zhou C
Acta Pharm Sin B; 2021 Oct; 11(10):2983-2994. PubMed ID: 34729299
[TBL] [Abstract][Full Text] [Related]
11. Role of DNA repair defects in predicting immunotherapy response.
Zhang J; Shih DJH; Lin SY
Biomark Res; 2020; 8():23. PubMed ID: 32612833
[TBL] [Abstract][Full Text] [Related]
12. Diverse immune response of DNA damage repair-deficient tumors.
Qing T; Jun T; Lindblad KE; Lujambio A; Marczyk M; Pusztai L; Huang KL
Cell Rep Med; 2021 May; 2(5):100276. PubMed ID: 34095878
[TBL] [Abstract][Full Text] [Related]
13. Triple kill: DDR inhibitors, radiotherapy and immunotherapy leave cancer cells with no escape.
Qiu Y; Hu X; Zeng X; Wang H
Acta Biochim Biophys Sin (Shanghai); 2022 Oct; 54(11):1569-1576. PubMed ID: 36305726
[TBL] [Abstract][Full Text] [Related]
14. DNA Repair Deficiency Regulates Immunity Response in Cancers: Molecular Mechanism and Approaches for Combining Immunotherapy.
Xu Y; Nowsheen S; Deng M
Cancers (Basel); 2023 Mar; 15(5):. PubMed ID: 36900418
[TBL] [Abstract][Full Text] [Related]
15. Lovastatin/SN38 co-loaded liposomes amplified ICB therapeutic effect via remodeling the immunologically-cold colon tumor and synergized stimulation of cGAS-STING pathway.
Yang Y; Qi J; Hu J; Zhou Y; Zheng J; Deng W; Inam M; Guo J; Xie Y; Li Y; Xu C; Deng W; Chen W
Cancer Lett; 2024 Apr; 588():216765. PubMed ID: 38408604
[TBL] [Abstract][Full Text] [Related]
16. DNA Damage and Cancer Immunotherapy: A STING in the Tale.
Reisländer T; Groelly FJ; Tarsounas M
Mol Cell; 2020 Oct; 80(1):21-28. PubMed ID: 32810436
[TBL] [Abstract][Full Text] [Related]
17. DNA damage repair gene mutations and their association with tumor immune regulatory gene expression in muscle invasive bladder cancer subtypes.
Vidotto T; Nersesian S; Graham C; Siemens DR; Koti M
J Immunother Cancer; 2019 Jun; 7(1):148. PubMed ID: 31174611
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic Targeting of DNA Damage Repair in the Era of Precision Oncology and Immune Checkpoint Inhibitors.
Clark CA; Yang ES
J Immunother Precis Oncol; 2023 Feb; 6(1):31-49. PubMed ID: 36751656
[TBL] [Abstract][Full Text] [Related]
19. Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.
Parikh AR; He Y; Hong TS; Corcoran RB; Clark JW; Ryan DP; Zou L; Ting DT; Catenacci DV; Chao J; Fakih M; Klempner SJ; Ross JS; Frampton GM; Miller VA; Ali SM; Schrock AB
Oncologist; 2019 Oct; 24(10):1340-1347. PubMed ID: 31040255
[TBL] [Abstract][Full Text] [Related]
20. A score of DNA damage repair pathway with the predictive ability for chemotherapy and immunotherapy is strongly associated with immune signaling pathway in pan-cancer.
Ding K; He Y; Wei J; Fu S; Wang J; Chen Z; Zhang H; Qu Y; Liang K; Gong X; Qiu L; Chen D; Xiao B; Du H
Front Immunol; 2022; 13():943090. PubMed ID: 36081518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
